Similarity-based modeling applied to signal detection in pharmacovigilance

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 9, 2014, Pages

  Vilar, S ^a,b   Ryan, P B ^b,c   Madiganx, D ^a,b   Stang, P E ^b,c   Schuemie, M J ^b,c   Friedman, C ^a,b   Tatonetti, N P ^a,b,d   Hripcsak, G ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Observational Health Data Sciences and Informatics   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; CHEMICAL STRUCTURE; DATA ANALYSIS; DATA MINING; DRUG CONFORMATION; DRUG DATABASE; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; FOLLOW UP; MOLECULAR MODEL; PRIORITY JOURNAL; SIGNAL DETECTION;

EID: 84924624974     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.35     Document Type: Article

References (47)

1. Hripcsak, G. & Albers, D.J. Next-generation phenotyping of electronic health records. J. Am. Med. Inform. Assoc. 20, 117-121 (2013).
2. The Truven MarketScan Commercial Claims and Encounters (CCAE). . Accessed 1 September 2013.
3. FDA U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). . Accessed 1 September 2013.
4. Wang, X., Hripcsak, G., Markatou, M. & Friedman, C. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. J. Am. Med. Inform. Assoc. 16, 328-337 (2009).
5. Hauben, M., Madigan, D., Gerrits, C.M., Walsh, L. & Van Puijenbroek, E.P. The role of data mining in pharmacovigilance. Expert Opin. Drug Saf. 4, 929-948 (2005).
6. Honig, P.K. Advancing the science of pharmacovigilance. Clin. Pharmacol. Ther. 93, 474-475 (2013).
7. Almenoff, J.S., Pattishall, E.N., Gibbs, T.G., DuMouchel, W., Evans, S.J. & Yuen, N. Novel statistical tools for monitoring the safety of marketed drugs. Clin. Pharmacol. Ther. 82, 157-166 (2007).
8. Harpaz, R., DuMouchel, W., LePendu, P., Bauer-Mehren, A., Ryan, P. & Shah, N.H. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin. Pharmacol. Ther. 93, 539-546 (2013).
9. van Puijenbroek, E.P., Egberts, A.C., Heerdink, E.R. & Leufkens, H.G. Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur. J. Clin. Pharmacol. 56, 733-738 (2000).
10. Hauben, M. & Bate, A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov. Today. 14, 343-357 (2009).
11. Ryan, P.B. et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 36 (suppl. 1), S143-S158 (2013).
12. Ryan, P.B., Madigan, D., Stang, P.E., Overhage, J.M., Racoosin, J.A. & Hartzema, A.G. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat. Med. 31, 4401-4415 (2012).
13. Ryan, P.B. & Schuemie, M.J. Evaluating performance of risk identification methods through a large-scale simulation of observational data. Drug Saf. 36 (suppl. 1), S171-S180 (2013).
14. Schuemie, M.J., Madigan, D. & Ryan, P.B. Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system. Drug Saf. 36 (suppl. 1), S133-S142 (2013).
15. DuMouchel, W., Ryan, P.B., Schuemie, M.J. & Madigan, D. Evaluation of disproportionality safety signaling applied to healthcare databases. Drug Saf. 36 (suppl. 1), S123-S132 (2013).
16. Ryan, P.B., Schuemie, M.J. & Madigan, D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 36 (suppl. 1), S95-106 (2013).
17. Holmes, A.B., Hawson, A., Liu, F., Friedman, C., Khiabanian, H. & Rabadan, R. Discovering disease associations by integrating electronic clinical data and medical literature. PLoS One 6, e21132 (2011).
18. Reese, J.A. et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood. 116, 2127-2133 (2010).
19. Harpaz, R. et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J. Am. Med. Inform. Assoc. 20, 413-419 (2013).
20. Ryan, P.B., Madigan, D., Stang, P.E., Schuemie, M.J. & Hripcsak, G. Medication-wide association studies. CPT Pharmacometrics Syst. Pharmacol. 2, e76 (2013).
21. Vilar, S., Harpaz, R., Santana, L., Uriarte, E. & Friedman, C. Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis. PLoS One. 7, e41471 (2012).
22. Vilar, S., Harpaz, R., Chase, H.S., Costanzi, S., Rabadan, R. & Friedman, C. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J. Am. Med. Inform. Assoc. 18 (suppl. 1), i73-i80 (2011).
23. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. . Accessed 15 November 2013.
24. Sacre, S., Medghalchi, M., Gregory, B., Brennan, F. & Williams, R. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum. 62, 683-693 (2010).
25. Andrade, C., Sandarsh, S., Chethan, K.B. & Nagesh, K.S. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J. Clin. Psychiatry. 71, 1565-1575 (2010).
26. Mellemkjaer, L. et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br. J. Clin. Pharmacol. 53, 173-181 (2002).
27. Wallace, J.L. How do NSAIDs cause ulcer disease? Baillieres. Best Pract. Res. Clin. Gastroenterol. 14, 147-159 (2000).
28. Schafer, A.I. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J. Clin. Pharmacol. 35, 209-219 (1995).
29. DrugBank database, version 3.0. . Accessed 1 September 2013.
30. Van Solingen, R.M. et al. Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin. Am. J. Med. 111, 285-289 (2001).
31. Drugdex ' System (Micromedex Healthcare Series). Greenwood Village, CO: Thomson Reuters (Healthcare) Inc., 2011.
32. Tu, X. et al. Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury. J. Am. Soc. Nephrol. 19, 77-83 (2008).
33. Vallurupalli, N.G. & Goldhaber, S.Z. Gastrointestinal complications of dual antiplatelet therapy. Circulation 113, e655-e658 (2006).
34. Meyboom, R.H., Egberts, A.C., Edwards, I.R., Hekster, Y.A., de Koning, F.H. & Gribnau, F.W. Principles of signal detection in pharmacovigilance. Drug Saf. 16, 355-365 (1997).
35. Bolton, E.E. et al. PubChem3D: a new resource for scientists. J. Cheminform. 3, 32 (2011).
36. The PubChem Project. . Accessed 1 September 2013.
37. Suchard, M.A., Zorych, I., Simpson, S.E., Schuemie, M.J., Ryan, P.B. & Madigan, D. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. Drug Saf. 36 (suppl. 1), S83-S93 (2013).
38. Simpson, S.E., Madigan, D., Zorych, I., Schuemie, M.J., Ryan, P.B. & Suchard, M.A. Multiple self-controlled case series for large-scale longitudinal observational databases. Biometrics 69, 893-902 (2013).
39. Durant, J.L., Leland, B.A., Henry, D.R. & Nourse, J.G. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf. Comput. Sci. 42, 1273-1280 (2002).
40. Daylight, Chemical Information Systems, Inc. . Accessed 1 December 2011.
41. Vilar, S., Harpaz, R., Uriarte, E., Santana, L., Rabadan, R. & Friedman, C. Drug-drug interaction through molecular structure similarity analysis. J. Am. Med. Inform. Assoc. 19, 1066-1074 (2012).
42. LigPrep, version 2.5. Schrödinger, LLC, New York, USA. (2011). Accessed 1 October 2013.
43. Kaminski, G.A., Friesner, R.A., Tirado-Rives, J. & Jorgensen, W.L. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J. Phys. Chem. B. 105, 6474-6487 (2001).
44. MacroModel, version 9.9. Schrödinger, LLC, New York, NY. (2011) Accessed 1 October 2013.
45. Phase, version 3.3. Schrödinger, LLC, New York, USA. (2011) Accessed 1 October 2013).
46. SIDER Side Effect Resource. . Accessed 15 May 2013.
47. WHO Collaborating Centre for Drug Statistics Methodology (WHOCC). . Accessed 15 October 2013.